Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

NCT02640755

Solid Malignancies

COMPLETED PHASE1

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

NCT00501605

Advanced Solid Tumor Liver Metastases

COMPLETED PHASE1

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

NCT00243347

Carcinoma Non-Small-Cell Lung Carcinoma Head and Neck Neoplasms

COMPLETED PHASE1

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

NCT01026402

Advanced Solid Malignancies

COMPLETED PHASE1

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

NCT00502567

Advanced Solid Tumor

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Metastatic Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD2171

oral 14C

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cediranib RECENTIN™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed metastatic tumor which is refractory to standard therapies
* life expectancy is 12 weeks or longer
* WHO performance status is 0-12

Exclusion Criteria

* radiotherapy and chemotherapy within 4 weeks before the start of the study treatment
* patients with a history of poorly controlled hypertension
* history or evidence of any medical condition that might affect gastrointestinal function
* patients that have participated in a radiolabelled study in the last 5 years

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No